The Ema, while admitting the existence of a link between the administration of the AstraZeneca vaccine and rare thrombosis, reaffirms the safety of the drug. In the meantime, Italy is preparing to limit its use only to those over 60.
New controversies, new fears, one new verification of the data available to the European Medicines Agency. And a new one confirmation on security of the anti-Covid vaccine made by AstraZeneca. The Ema reiterated that – despite the existence of a “bond“Between administration and”rare cases of cerebral venous thrombosis“ – the treatment can continue to be used safely. According to what was verified by the Prac – the Internal Risk Assessment Committee of the EMA – “Unusual blood clots with low platelets will need to be listed as a very rare side effect Vaxzevria“, Current name of the vaccine AstraZeneca.
During the verification, the experts of the regulatory agency explained, no “age-related risk factors“, though “most cases occurred in women under the age of 60” ed “within 2 weeks of the first dose“While the incidence of suspected cases after the second dose”it is limited“, Explains the institution.
The existence of a relationship between the Anglo-Swedish drug and thrombosis is not proven: but the increase in cases suggests that, while waiting for the link to be traced and scientifically explained, a link exists. Take for example the case ofEngland, the country that more than anyone else has exploited the vaccine AstraZeneca: the suspected cases are in total 76, with 19 deaths. The data, provided by the British drug authority – the Mhra – and show how, among the deceased, three people were under 30 years old. On the basis of this information, the British agency considered it necessary to intervene, establishing that people between 18 and 29 years old should be given a different vaccine.
“All cases“, He explains June Raine, of the Mhra “occurred after the first dose was given“. The incidence of cases remains very rare: 4 cases in a million. “Anyone who has persistent symptoms after 4 days or more should seek medical attention“, Explained Raine, however, and advised to react quickly in the event of”persistent acute headache, blurred vision, shortness of breath, chest pain, leg swelling, persistent abdominal pain and unusual bruising or localized spots on the skin other than the injection mark“.
AstraZeneca, Italy ready to recommend it only to over 60s
As far as our country is concerned, the hypothesis of an intervention that limits the use of the drug to people with at least 60 years old, despite the few tests carried out on this age group. To announce it, even if the decision has not yet been made official, was the President of the Superior Health Council Franco Locatelli, who however added, for those who have already been vaccinated: “We have no elements to discourage the administration of the second dose“.
The risk is that the distrust against the vaccine treatment carried out by AstraZeneca go to strengthen. A circumstance which, combined with the organizational gaps and the scarcity of available doses, risks undermining the Italian vaccination campaign even more, far from the objectives initially set: the 500 thousand daily vaccinations which, by the end of April, the extraordinary commissioner Francesco Paolo Figliuolo stated to aim remain a chimera.